Skip to content

Study · Randomized controlled trial · 2018

9 results

Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.

Martinez R, Al-Jobori H, Ali AM, Adams J, Abdul-Ghani M, Triplitt C, DeFronzo RA, DeFronzo RA, Cersosimo E

Diabetes30 Mar 2018Cited by 45 (Europe PMC)

PMID29602791 (opens in a new tab)PMCIDPMC7301339 (opens in a new tab)DOI10.2337/db17-1278 (opens in a new tab)PepBankPUB-29602791
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the fall in endogenous glucose production with liraglutide alone was the same as before treatment, whereas canagliflozin attenuated it.

    In plain wordsIn adults with type 2 diabetes, liraglutide alone did not change how much glucose production fell, unlike canagliflozin.

    Peptide
    Liraglutide
    Outcome
    No significant changeDecrement in endogenous glucose production (EGP) with liraglutide alone
    Study

    n: not reported in source

    Comparator
    Pretreatment study
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas with LIRA it was the same (2.4 ± 0.2 to 1.8 ± 0.2 mg/kg ⋅ min) (all P < 0.05 vs. baseline).
    2 context sentences
    Summary · context
    Subjects with type 2 diabetes (n = 36) were randomized to 1) canagliflozin (CANA), 2) liraglutide (LIRA), or 3) CANA plus LIRA (CANA/LIRA).
    Summary · context
    EGP was measured with [3-3H]glucose with or without drugs for 360 min.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, fasting plasma insulin remained unchanged with liraglutide alone.

    In plain wordsIn adults with type 2 diabetes, fasting insulin stayed the same with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeFasting plasma insulin with liraglutide alone
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Fasting plasma insulin
    18 μU/mL
    LIRA, before
    Fasting plasma insulin
    16 μU/mL
    LIRA, after

    Source sentences

    Summary
    while it remained unchanged in LIRA (18 ± 2 vs. 16 ± 2 μU/mL)
    2 context sentences
    Summary · context
    Subjects with type 2 diabetes (n = 36) were randomized to 1) canagliflozin (CANA), 2) liraglutide (LIRA), or 3) CANA plus LIRA (CANA/LIRA).
    Summary · context
    EGP was measured with [3-3H]glucose with or without drugs for 360 min.
  3. 03HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes, mean plasma glucagon decreased with liraglutide alone.

    In plain wordsIn adults with type 2 diabetes, liraglutide alone lowered the hormone glucagon.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma glucagon with liraglutide alone
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Plasma glucagon
    93 pg/mL
    LIRA, start
    Plasma glucagon
    80 pg/mL
    LIRA, end

    Source sentences

    Summary
    decreased with LIRA (93 ± 6 to 80 ± 6 pg/mL, P < 0.05)
    2 context sentences
    Summary · context
    Subjects with type 2 diabetes (n = 36) were randomized to 1) canagliflozin (CANA), 2) liraglutide (LIRA), or 3) CANA plus LIRA (CANA/LIRA).
    Summary · context
    EGP was measured with [3-3H]glucose with or without drugs for 360 min.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, adding liraglutide to canagliflozin prevented the insulin decline seen with canagliflozin alone.

    In plain wordsAdding liraglutide to canagliflozin stopped the fall in insulin that canagliflozin caused alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseFasting plasma insulin decline with canagliflozin, with versus without liraglutide
    Study

    n: not reported in source

    Comparator
    Canagliflozin alone
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LIRA prevented the insulin decline and blocked the glucagon rise observed with CANA but did not inhibit the increase in EGP.
    2 context sentences
    Summary · context
    Subjects with type 2 diabetes (n = 36) were randomized to 1) canagliflozin (CANA), 2) liraglutide (LIRA), or 3) CANA plus LIRA (CANA/LIRA).
    Summary · context
    EGP was measured with [3-3H]glucose with or without drugs for 360 min.
  5. 05HumanRandomized controlled trialMechanism

    In adults with type 2 diabetes, adding liraglutide to canagliflozin blocked the glucagon rise seen with canagliflozin alone.

    In plain wordsAdding liraglutide to canagliflozin blocked the glucagon rise that canagliflozin caused alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlucagon rise with canagliflozin, with versus without liraglutide
    Study

    n: not reported in source

    Comparator
    Canagliflozin alone
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LIRA prevented the insulin decline and blocked the glucagon rise observed with CANA but did not inhibit the increase in EGP.
    2 context sentences
    Summary · context
    Subjects with type 2 diabetes (n = 36) were randomized to 1) canagliflozin (CANA), 2) liraglutide (LIRA), or 3) CANA plus LIRA (CANA/LIRA).
    Summary · context
    EGP was measured with [3-3H]glucose with or without drugs for 360 min.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, adding liraglutide to canagliflozin did not inhibit the increase in endogenous glucose production seen with canagliflozin alone.

    In plain wordsAdding liraglutide did not stop the rise in glucose production that canagliflozin caused.

    Peptide
    Liraglutide
    Outcome
    No significant changeEndogenous glucose production increase with canagliflozin, with versus without liraglutide
    Study

    n: not reported in source

    Comparator
    Canagliflozin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LIRA prevented the insulin decline and blocked the glucagon rise observed with CANA but did not inhibit the increase in EGP.
    2 context sentences
    Summary · context
    Subjects with type 2 diabetes (n = 36) were randomized to 1) canagliflozin (CANA), 2) liraglutide (LIRA), or 3) CANA plus LIRA (CANA/LIRA).
    Summary · context
    EGP was measured with [3-3H]glucose with or without drugs for 360 min.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the combination of canagliflozin and liraglutide attenuated the fall in endogenous glucose production compared with the pretreatment study.

    In plain wordsCanagliflozin plus liraglutide reduced how much glucose production fell, compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseDecrement in endogenous glucose production with canagliflozin plus liraglutide
    Study

    n: not reported in source

    Comparator
    Pretreatment study
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The decrement in EGP was attenuated with CANA (2.1 ± 0.1 to 1.9 ± 0.1 mg/kg ⋅ min) and CANA/LIRA (2.2 ± 0.1 to 2.0 ± 0.1 mg/kg ⋅ min)
    2 context sentences
    Summary · context
    Subjects with type 2 diabetes (n = 36) were randomized to 1) canagliflozin (CANA), 2) liraglutide (LIRA), or 3) CANA plus LIRA (CANA/LIRA).
    Summary · context
    EGP was measured with [3-3H]glucose with or without drugs for 360 min.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, fasting plasma insulin remained unchanged with canagliflozin plus liraglutide.

    In plain wordsFasting insulin stayed the same with canagliflozin plus liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeFasting plasma insulin with canagliflozin plus liraglutide
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    while it remained unchanged in LIRA (18 ± 2 vs. 16 ± 2 μU/mL) and CANA/LIRA (17 ± 1 vs. 15 ± 2 μU/mL).
    2 context sentences
    Summary · context
    Subjects with type 2 diabetes (n = 36) were randomized to 1) canagliflozin (CANA), 2) liraglutide (LIRA), or 3) CANA plus LIRA (CANA/LIRA).
    Summary · context
    EGP was measured with [3-3H]glucose with or without drugs for 360 min.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 09HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism

    In adults with type 2 diabetes, plasma glucagon did not change with canagliflozin plus liraglutide.

    In plain wordsGlucagon did not change with canagliflozin plus liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changePlasma glucagon with canagliflozin plus liraglutide
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    and did not change in CANA/LIRA.
    2 context sentences
    Summary · context
    Subjects with type 2 diabetes (n = 36) were randomized to 1) canagliflozin (CANA), 2) liraglutide (LIRA), or 3) CANA plus LIRA (CANA/LIRA).
    Summary · context
    EGP was measured with [3-3H]glucose with or without drugs for 360 min.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.